Search

Your search keyword '"Ozet, Ahmet"' showing total 357 results
Start Over Author "Ozet, Ahmet"
357 results on '"Ozet, Ahmet"'

3. Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group Study

Author

BirYucel, Kadriye, primary, Uğraklı, Muzaffer, additional, Sekmek, Serhat, additional, Yıldırım, Nilgün, additional, Gürler, Fatih, additional, Yazıcı, Ozan, additional, Ozet, Ahmet, additional, Bal, Öznur, additional, Araz, Murat, additional, Artaç, Mehmet, additional, and Ozdemir, Nuriye, additional

Published
2024
Full Text
View/download PDF

9. Experience from Turkish centers participating in the Early Access Program (EAP): Preliminary real-world safety data of nivolumab (nivo) combined with ipilimumab (ipi) in pre-treated advanced melanoma patients

Author

Karadurmus, Nuri, Nahit Sendur, Mehmet Ali, Karaca, Burcak, Olmez, Omer Fatih, Hacibekiroglu, Ilhan, Coskun, Hasan Senol, Degirmencioglu, Serkan, Kemal, Yasemin, Kilickap, Saadettin, Sumbul, Ahmet Taner, Aydin, Burc, Turna, Hande, Kaplan, Muhammet Ali, Babacan, Nalan, Demirci, Umut, Ata, Alper, Erdem, Dilek, Ozet, Ahmet, and Abali, Huseyin

Published
2018
Full Text
View/download PDF

10. Human Development Index and its association with staff spiritual care provision: a Middle Eastern oncology study

Author

Bar-Sela, Gil, Schultz, Michael J., Elshamy, Karima, Rassouli, Maryam, Ben-Arye, Eran, Doumit, Myrna, Gafer, Nahla, Albashayreh, Alaa, Ghrayeb, Ibtisam, Turker, Ibrahim, Ozalp, Gulcin, Kav, Sultan, Fahmi, Rasha, Nestoros, Sophia, Ghali, Hasanein, Mula-Hussain, Layth, Shazar, Ilana, Obeidat, Rana, Punjwani, Rehana, Khleif, Mohamad, Can, Gulbeyaz, Tuncel, Gonca, Charalambous, Haris, Faraj, Safa, Keoppi, Neophyta, Al-Jadiry, Mazin, Postovsky, Sergey, Al-Omari, Ma’an, Razzaq, Samaher, Ayyash, Hani, Khader, Khaled, Kebudi, Rejin, Omran, Suha, Rasheed, Osaid, Qadire, Mohammed, Ozet, Ahmet, and Silbermann, Michael

Published
2019
Full Text
View/download PDF

13. Evaluation of PIV Score as a Predictor Biomarker for Pathologically Proven Intermediate-High Risk Gastric strointestinal Stromal Tumors.

Author

Unsal, Oktay and Ozet, Ahmet

Subjects
BIOMARKERS, ADJUVANT chemotherapy, PREDICTIVE tests, INFLAMMATION, PATHOLOGY, RETROSPECTIVE studies, GASTROINTESTINAL tumors, SOFT tissue tumors, RISK assessment, CANCER patients, PLATELET count, DESCRIPTIVE statistics, PREDICTION models, CANCER patient medical care
Abstract

Objectives: Pan-immune-inflammation value (PIV) score has been started to be used as a prognostic tool in cancer patients trendly in recent years. In this study, we aimed to evaluate the PIV score in patients with pathologically-proven intermediate-high risk gastric GIST to guide adjuvant therapy and to get better prognosis. Methods: Patients followed up by Medical Oncology clinic with a diagnosis of gastric GIST were evaluated retrospectively. Results: A total of 41 patients with a diagnosis of gastric GIST were examined. When the tumors were analyzed according to the AFIP prognostic model, 23 patients were identified as intermediate-high-risk tumors. According to the modified NIH model, intermediate-high risk tumors were noted in 26 patients. According to AFIP prognostic model, PIV scores were not different between risk groups (p=0.27). When the patients were classified according to modified NIH model, the platelet counts in patients with intermediate-high risk tumor were significanly higher than the other patients group (p=0.01). In addition, PIV scores were significantly higher in patients with intermediate-high risk tumor than other patients (p=0.03). Conclusion: This study displayed that PIV score can be useful as a risk predictor in patients with gastric GIST. Future prospective analysis are needed to support our results. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Prognostic Significance of the Gustave-Roussy Immune Score in Colon Cancer Patients Treated with Adjuvant CAPEOX Regimen.

Author

Yucel, Kadriye Bir, Sutcuoglu, Osman, Ugur, Tuba, Cagdaser, Cisem, Yazici, Ozan, Ozet, Ahmet, and Ozdemir, Nuriye

Subjects
THERAPEUTIC use of antimetabolites, THERAPEUTIC use of antineoplastic agents, COLON tumors, ALBUMINS, REFERENCE values, STATISTICS, MULTIVARIATE analysis, RETROSPECTIVE studies, FISHER exact test, TUMOR classification, NEUTROPHIL lymphocyte ratio, LACTATE dehydrogenase, DESCRIPTIVE statistics, CHI-squared test, KAPLAN-Meier estimator, OXALIPLATIN, DATA analysis software, OVERALL survival, PROPORTIONAL hazards models
Abstract

Objectives: The aim of this research was to assess the prognostic value of Gustave-Roussy immune score (GRIm-Score) in stage II and III colon cancer patients receiving capecitabine and oxaliplatin (CAPEOX). Methods: Serum lactate dehydrogenase (LDH), neutrophil-to-lymphocyte ratio (NLR), and albumin levels were used to create the GRIm-Score. The GRIm-score was obtained with the sum of these three laboratory parameters, which were scored as 0 and 1 according to the cut-off values. A homogeneous patient group (high-risk stage II and stage III patients) was classified into two groups, one with a high GRIm-Score (score 2 and 3) and the other with a low GRIm-Score (score 0 and 1). Results: The 4-year recurrence-free survival (RFS) was 60% in the GRIm-Score high group and 94.4% in the GRIm-Score low group (p<0.001). The 4-year overall survival (OS) was 78.1% in the GRIm-Score high group and 93.8% in the GRIm- Score low group (p<0.001). Additionally, multivariable analyses revealed that GRIm-Score (HR: 4.226, 95% CI: 1.953-9.143, p <0.001) was an independent prognostic marker for OS. Conclusion: High GRIm-Score was significantly related to poor OS in stage II and III colon cancer patients who received CAPEOX. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

15. COVID-19 Infection After Different Combinations of Vaccines in Patients with Solid Tumors.

Author

Unsal, Oktay, Yazici, Ozan, Ozdemir, Nuriye, Savas, Gozde, and Ozet, Ahmet

Subjects
COVID-19, COVID-19 vaccines, FISHER exact test, CANCER patients, VACCINE effectiveness, DESCRIPTIVE statistics, DATA analysis software, LOGISTIC regression analysis
Abstract

Objectives: This study aimed to evaluate the cancer patients with COVID-19 infection after receiving different combinations of the COVID-19 vaccines for effective vaccination strategies. Methods: Eighty nine point thirty three percent (89.33%) of 3832 with solid malignancy were received at least 2 doses of COVID-19 vaccine. A total of 167 cancer patients with COVID-19 infection at least 28 days after the last dose of COVID- 19 vaccine were included in the study. Results: Forty one point nine percent (41.9%) of the study population were received two doses of CoronaVac vaccine, 21.5% of the them; two doses of CoronaVac vaccine and one dose of BNT162b2 vaccine, 18.6% of them; two doses of BNT162b2 vaccine and 18% of them; three doses of CoronaVac vaccine. The median day from the last dose of vaccination to infection was significantly longer in patients with receiving cytotoxic chemotherapy than others (p=0.02). The requirement of oxygen support was high numerically in patients received the last of cytotoxic chemotherapy in 1-14 days prior to COVID-19 infection (23%). Conclusion: This study outlined the similar efficacy of the different combinations of COVID-19 vaccine by evaluating the clinical parameters in patients with solid malignancy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

17. Ezrin is a prognostic biomarker in patients with clear cell metastatic renal cell carcinoma receiving sunitinib

Author

Cetin, Bulent, Gonul, Ipek, Gumusay, Ozge, Afsar, Baris, Bilgetekin, Irem, Ozet, Ahmet, and Uner, Aytug

Subjects
Carcinoma, Renal cell -- Drug therapy -- Prognosis -- Patient outcomes, Membrane proteins -- Health aspects -- Physiological aspects, Health
Abstract

Byline: Bulent. Cetin, Ipek. Gonul, Ozge. Gumusay, Baris. Afsar, Irem. Bilgetekin, Ahmet. Ozet, Aytug. Uner Objective: Sunitinib is a novel oral multitargeted tyrosine kinase inhibitor with antitumor and antiangiogenic activities. [...]

Published
2021

18. Correction to: Human Development Index and its association with staff spiritual care provision: a Middle Eastern oncology study

Author

Bar-Sela, Gil, Schultz, Michael J., Elshamy, Karima, Rassouli, Maryam, Ben-Arye, Eran, Doumit, Myrna, Gafer, Nahla, Albashayreh, Alaa, Ghrayeb, Ibtisam, Turker, Ibrahim, Ozalp, Gulcin, Kav, Sultan, Fahmi, Rasha, Nestoros, Sophia, Ghali, Hasanein, Mula-Hussain, Layth, Shazar, Ilana, Obeidat, Rana, Punjwani, Rehana, Khleif, Mohamad, Can, Gulbeyaz, Tuncel, Gonca, Charalambous, Haris, Faraj, Safa, Keoppi, Neophyta, Al-Jadiry, Mazin, Postovsky, Sergey, Al-Omari, Ma’an, Razzaq, Samaher, Ayyash, Hani, Khader, Khaled, Kebudi, Rejin, Omran, Suha, Rasheed, Osaid, Qadire, Mohammed, Ozet, Ahmet, and Silbermann, Michael

Published
2019
Full Text
View/download PDF

19. Efficacy of nivolumab as second-line treatment for elderly patients with metastatic malign melanoma.

Author

Unsal, Oktay, Yazici, Ozan, Ozdemir, Nuriye, and Ozet, Ahmet

Subjects
NIVOLUMAB, MELANOMA, SERUM, CREATININE, CANCER chemotherapy
Abstract

Aim: This study aimed to analyse the clinical characteristics, effectiveness and safety of nivolumab monotherapy in patients aged ≥ 65 years with metastatic melanoma. Materials and Methods: This study involved patients aged ≥65 years who were diagnosed with metastatic cutaneous or mucosal melanoma. Patients with BRAF wild type, ECOG performance status 0-1, and who had previously received one line of chemotherapy were included, irrespective of PD-L1 expression. The study analyzed PFS, OS, and adverse event profiles. Results: Twenty-one patients, with a median age of 70, were analysed in the study. The median PFS for nivolumab as second-line therapy in elderly patients was 3.5 months (95% CI, 1.5 to 5.6 months), while the median OS was 14.5 months (95% CI, 10.3 to 18.6 months). The most common grade 1-2 adverse events were anemia (66.7%) and serum creatinine increase (23.8%). Additionally, the rate of grade 3-4 adverse events due to all causes was 28.6%. There was no grade 5 adverse event. Conclusion: Nivolumab is effective and safe as second-line therapy in patients aged ≥65 years with metastatic melanoma. It is a tolerable and effective treatment choice for elderly patients who cannot received nivolumab in first line therapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

20. Prognostic and predictive factors in cancer patients with obstructive jaundice treated by percutaneous transhepatic biliary drainage: A single-center experience

Author

Sahinli, Hayriye and Ozet, Ahmet

Subjects
Jaundice -- Care and treatment -- Prognosis, Cancer patients -- Care and treatment, Health
Abstract

Byline: Hayriye. Sahinli, Ahmet. Özet Background: Short-term survival rates are reported in the patients undergoing percutaneous transhepatic biliary drainage (PTBD). The purpose of this study was to determine the factors [...]

Published
2020

21. Good prognostic factor in patients with nonmetastatic nasopharyngeal carcinoma: Programmed death ligand-1 expression in tumor cells

Author

Sahinli, Hayriye, Akyurek, Nalan, Yilmaz, Mukaddes, Kandemir, Olcay, Duran, Ayse, Kulacoglu, Sezer, Ucar, Gokhan, Acar, Elif, Ozet, Ahmet, Oksuzoglu, O., and Ozdemir, Nuriye

Subjects
Nasopharyngeal cancer -- Care and treatment -- Prognosis, Carcinoma -- Care and treatment -- Prognosis, Membrane proteins -- Health aspects, Cancer -- Care and treatment -- Prognosis, Health
Abstract

Byline: Hayriye. Sahinli, Nalan. Akyürek, Mukaddes. Yilmaz, Olcay. Kandemir, Ayse. Duran, Sezer. Kulaçoglu, Gökhan. Uçar, Elif. Acar, Ahmet. Özet, O. Öksüzoglu, Nuriye. Özdemir Purpose: Programmed death ligand-1 (PD-L1) is the [...]

Published
2020

22. Is there any relationship between Helicobacter pylori infection and human epidermal growth factor receptor 2 expression in gastric cancer?

Author

Algin, Efnan, Baykara, Meltem, Yilmaz, Guldal, Cetin, Bulent, Ekinci, Ozgur, Uner, Aytug, and Ozet, Ahmet

Subjects
Helicobacter infections -- Diagnosis -- Development and progression, Stomach cancer -- Diagnosis -- Development and progression, Health
Abstract

Byline: Efnan. Algin, Meltem. Baykara, Guldal. Yilmaz, Bulent. Cetin, Ozgur. Ekinci, Aytug. Uner, Ahmet. Ozet Purpose: Helicobacter pylori(HP) is a significant causative agent of gastric cancer (GC). However, the underlying [...]

Published
2020

27. A metastatic histiocytic sarcoma case with primary involvement of the tonsil

Author

Aytekin, Aydin, Ozet, Ahmet, Bilgetekin, Irem, Ogut, Betul, Ciltas, Aydin, and Benekli, Mustafa

Subjects
Vincristine, Carboplatin, Sarcoma -- Diagnosis, Cancer metastasis -- Diagnosis, Health
Abstract

Byline: Aydin. Aytekin, Ahmet. Ozet, Irem. Bilgetekin, Betul. Ogut, Aydin. Ciltas, Mustafa. Benekli Histiocytic sarcoma (HS) is an extremely rare and aggressive hematopoietic tumor. Although it can be seen at [...]

Published
2020

29. Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers

Author

Baykara, Meltem, Benekli, Mustafa, Ekinci, Ozgur, Irkkan, Sultan Cigdem, Karaca, Halit, Demirci, Umut, Akinci, Muhammed Bulent, Unal, Olcun Umit, Dane, Faysal, Turkoz, Fatma Paksoy, Balakan, Ozan, Eser, Eylem Pinar, Ozturk, Selcuk Cemil, Ozkan, Metin, Oksuzoglu, Berna, Sevinc, Alper, Demir, Necla, Harputluoglu, Hakan, Yalcin, Bulent, Coskun, Ugur, Uner, Aytug, Ozet, Ahmet, Buyukberber, Suleyman, and for the Anatolian Society of Medical Oncology (ASMO)

Published
2015
Full Text
View/download PDF

33. Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy

Author

Karacin, Cengiz, primary, Eren, Tulay, additional, Zeynelgil, Esra, additional, Imamoglu, Goksen Inanc, additional, Altinbas, Mustafa, additional, Karadag, Ibrahim, additional, Basal, Fatma Bugdayci, additional, Bilgetekin, Irem, additional, Sutcuoglu, Osman, additional, Yazici, Ozan, additional, Ozdemir, Nuriye, additional, Ozet, Ahmet, additional, Yildiz, Yesim, additional, Esen, Selin Akturk, additional, Ucar, Gokhan, additional, Uncu, Dogan, additional, Dinc, Bedia, additional, Aykan, Musa Baris, additional, Erturk, İsmail, additional, Karadurmus, Nuri, additional, Civelek, Burak, additional, Çelik, İsmail, additional, Ergun, Yakup, additional, Dogan, Mutlu, additional, and Oksuzoglu, Omur Berna, additional

Published
2021
Full Text
View/download PDF

41. The Relationship Between Plexin C1 Overexpression and Survival in Hepatocellular Carcinoma: a Turkish Oncology Group (TOG) Study

Author

NazimTurhal, Serdar, primary, Dogan, Mutlu, additional, Esendagli, Guldal, additional, Artac, Mehmet, additional, Korkmaz, Levent, additional, Coskun, Hasan Senol, additional, Goker, Erdem, additional, PerranYumuk, Fulden, additional, Bilgetekin, Irem, additional, Kose, Fatih, additional, Uncu, Dogan, additional, Kavgaci, Halil, additional, Akyol, Gulen, additional, Ozet, Ahmet, additional, and Yagci, Tamer, additional

Published
2021
Full Text
View/download PDF

43. Hepatitis B and C rates are significantly increased in certain solid tumors: A large retrospective study

Author

Kocoglu, Hakan, Karaca, Mustafa, Tural, Deniz, Hocaoglu, Erhan, Okuturlar, Yildiz, Fetullahoglu, Zeynep, Gunaldi, Meral, Ciftci, Rumeysa, Tuna, Savas, Yuce, Orhan, Ozet, Gulsum, Ozet, Ahmet, and Benekli, Mustafa

Subjects
Hepatitis B -- Distribution, Cancer -- Complications and side effects, Hepatitis C -- Distribution, Health risk assessment -- Methods, Company distribution practices, Health
Abstract

Byline: Hakan. Kocoglu, Mustafa. Karaca, Deniz. Tural, Erhan. Hocaoglu, Yildiz. Okuturlar, Zeynep. Fetullahoglu, Meral. Gunaldi, Rumeysa. Ciftci, Savas. Tuna, Orhan. Yuce, Gulsum. Ozet, Ahmet. Ozet, Mustafa. Benekli Objective: Hepatitis B [...]

Published
2018

44. Ventricular bigeminal rhythm associated with trastuzumab: A potential cardiac side effect

Author

Karaca, Mustafa, Kocoglu, Hakan, Bilgetekin, Irem, Ozet, Ahmet, Sahinli, Hayriye, Demir, Hacer, Kankoc, Aykut, Tural, Deniz, and Yucel, Orhan

Subjects
Chemotherapy -- Usage, Antineoplastic agents -- Usage, Trastuzumab -- Usage, Breast cancer -- Patient outcomes, Health
Abstract

Byline: Mustafa. Karaca, Hakan. Kocoglu, Irem. Bilgetekin, Ahmet. Ozet, Hayriye. Sahinli, Hacer. Demir, Aykut. Kankoc, Deniz. Tural, Orhan. Yucel Cardiac side effects of targeted chemotherapy agents are getting more and [...]

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results